Jaguar Health's Napo Pharma announces expanded-access benefit of Crofelemer in congenital sodium diarrhea; plans NDA for MVID in mid-2027

Jaguar Health's Napo Pharmaceuticals announced an expanded-access benefit of Crofelemer in a congenital sodium diarrhea patient and plans to file an NDA for Crofelemer for MVID (microvillus inclusion disease) in mid-2027.

Detected & updated continuously · Source: Nebula